PRTT Protect Pharmaceutical Corp

PRTT status update announcement.

PRTT status update announcement.

Cheyenne, Wyoming, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corporation, Inc. (OTC:PRTT) informs, that the Share Exchange Agreement №1, signed on June 15, 2022 was not executed due to the insufficiency of legal instruments on the territory of the Republic of Belarus for conducting such transactions, and terminated on December 6, 2022.

The absence of an established agreement between the US and Belarus depositories and the lack of a legal basis for conducting transactions on the international exchange of securities caused the inability to perform the obligations.

According to par. 2.2-2.4 of the Agreement, the Parties shall had executed all legal obligations within 60 working days from the date of execution of the Agreement. As per September 6th, 2022 the obligations were not executed, and Parties agreed to extend the period for three more months.

As per December 6, 2022 the obligations were not executed, and the Parties mutually agreed to terminate the Agreement.

None of the terms of Agreement have been fulfilled by any of the Parties. The Parties have no claims against each other.

PRTT has prepared adjusted financial statements for the period of 2 and 3 quarters of 2022, taking into account the absence of any new assets and liabilities, based on the terms of termination of the Agreement.

About PRTT

Protect Pharmaceutical Corporation is a full-cycle software development and delivery company that produces, releases, and supports digital products for the business-to-business and business-to-consumer markets. The company’s expertise lies in custom software development and consulting services in Business automation, Artificial Intelligence, Machine Learning, Data Science, Big Data, Image recognition, Blockchain development, and cloud services. Its domain focus includes Supply chain, Logistics, Healthcare, Finance, Real estate, Legal, Insurance, Advertising, and more.

For more information contact:

Protect Pharmaceutical Corporation, Inc.

(347) 692 8942



EN
12/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Protect Pharmaceutical Corp

 PRESS RELEASE

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. We wanted to update shareholders in regards to the progress on our PCAOB Audit. We had a small delay that originated from the auditor needing physical access to a secure facility that houses customs products. We believe the delay will be minimal and are still on track to finalize our audit within the next week to two weeks. We apologize for the unforeseen dela...

 PRESS RELEASE

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. As we stated last week we are in the final stages of our PCAOB audit and expect its completion very soon. We have now responded to the open items to the auditor. We expect to receive the finalized audit report very soon and feel we can still meet our goal of completion before year end. As we end the year we are optimistic and believe that the company has accom...

 PRESS RELEASE

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As CEO of PRTT I wanted to update shareholders on current progress within the company. We posted our largest quarter for revenues for the second consecutive quarter. Our growth strategy is working and we recently announced the acquisition of Bosfor Export. This is one of several acquisition targets and we plan to continue to grow and expand not only our curr...

 PRESS RELEASE

Protect Pharmaceutical Corp. Acquires Bosfor Export

Protect Pharmaceutical Corp. Acquires Bosfor Export Istanbul, Turkey, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export. This strategic move has been financed through the issuance of 2,000,000 restricted shares, representing 100% ownership of Bosfor Export. Bosfor Export, known for its robust fruit wholesaling operations in Istanbul, currently achieves an annual revenue of approximately $28 million USD. With this acquisition, PRTT's management is optimistic about significantly increasing revenues by leveragi...

 PRESS RELEASE

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As we enter the 4th quarter we feel the company has entered a very pivotal time in our growth strategy. We posted our largest quarter for revenues in the second quarter of 2023 and our expansion goals and strategies are progressing very nicely. For the 6 months ending June 30, 2023 we had 62 million dollars in revenue with an operating profit of over 18 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch